Q4 2024 Merck & Co Inc Earnings Call Transcript
Key Points
- Merck & Co Inc (MRK) achieved strong growth in 2024, driven by demand for its innovative portfolio, including KEYTRUDA and the successful launch of WINREVAIR.
- The company reached nearly 0.5 billion people with its medicines and vaccines in 2024, showcasing its global impact.
- Merck & Co Inc (MRK) is making significant progress in its pipeline, with 20 potential new growth drivers, many with blockbuster potential.
- The Animal Health business delivered strong performance with a 13% sales growth.
- Merck & Co Inc (MRK) has a robust late-phase pipeline with promising developments in oncology, cardiometabolic, and infectious diseases.
- GARDASIL sales decreased by 18% due to lower demand in China, leading to elevated inventory levels.
- Merck & Co Inc (MRK) decided to temporarily pause GARDASIL shipments to China, impacting short-term revenue.
- The company faces challenges in the Chinese market for GARDASIL due to increased pressure on discretionary consumer spending.
- There is uncertainty regarding the timing of economic recovery in China, affecting long-term sales projections for GARDASIL.
- The Medicare Part D redesign is expected to negatively impact sales by approximately $400 million, affecting products like WINREVAIR and small molecule oncology products.
Thank you for standing by. Welcome to the Merck and Company Q4 sales and earnings conference call. (Operator Instructions) This call is being recorded. If you have any objections, you may disconnect at this time.
I would now like to turn the call over Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin.
Thank you, Shirley, and good morning everyone. Welcome to Merck's fourth-quarter 2024 conference call. Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer; Caroline Litchfield, Chief Financial Officer; and Dr. Dean Li, President of Merck Research Labs.
Before we get started, I'd like to point out that we have items in our GAAP results such as acquisition-related charges, restructuring costs, and certain other items that we have excluded from our non-GAAP results. There is a reconciliation in our press release.
I will also remind you that some of the statements that we make today may be
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
